FDAnews Drug Daily Bulletin

GSK Completes Transfer of Thrombosis Drugs to Aspen Group

Jan. 3, 2014

GlaxoSmithKline has completed the transfer of its thrombosis drugs Arixtra and Fraxiparine to the Aspen Group, which bought the brands for $1.2 billion, the UK drugmaker said Tuesday.

The sale is part of GSK’s strategy of divesting non-core brands in order to focus on drugs with greater growth potential, said GSK spokesperson Kalpesh Joshi. GSK’s partnership with Aspen goes back many years, he told Drug Daily Bulletin; in May of 2009, for example, Aspen took control of marketing and distribution of all of GSK’s drugs in South Africa.

Combined sales of Arixtra and Fraxiparine reached $293 million in the first half of 2013. Based on this, the company expects full-year sales figure to hit $578 million. — Lena Freund

Subscribe to Drug Industry Daily for complete coverage of the pharmaceutical industry. Click here for more information.